Skip to main content
Premium Trial:

Request an Annual Quote

Rubicon Genomics to Develop MethylPlex Tool for Prostate and Bladder Cancers

NEW YORK, Oct. 31 (GenomeWeb News) - Rubicon Genomics will work with Abbott Molecular to develop and sell its MethylPlex tool for detecting prostate and bladder cancers, Rubicon said today.


A methylation detection technology, MethylPlex detects patterns of abnormal DNA methylation in serum and urine during tumor formation and progression. Under the agreement, the tests will combine proprietary Rubicon methylation markers and a simplified method to detect them.


Abbott Molecular is a division of Abbott. Financial details for this agreement were not disclosed.

The Scan

Interfering With Invasive Mussels

The Chicago Tribune reports that researchers are studying whether RNA interference- or CRISPR-based approaches can combat invasive freshwater mussels.

Participation Analysis

A new study finds that women tend to participate less at scientific meetings but that some changes can lead to increased involvement, the Guardian reports.

Right Whales' Decline

A research study plans to use genetic analysis to gain insight into population decline among North American right whales, according to CBC.

Science Papers Tie Rare Mutations to Short Stature, Immunodeficiency; Present Single-Cell Transcriptomics Map

In Science this week: pair of mutations in one gene uncovered in brothers with short stature and immunodeficiency, and more.